The use of Roxifiban (DMP754), a novel oral platelet glycoprotein IIb/IIIa receptor inhibitor, in patients with stable coronary artery disease

American Journal of Cardiovascular Drugs

Volumn 3, Issue 2, 2003, Pages 101-112

  Murphy, Joseph ^a   Wright, R Scott ^a   Gussak, Ihor ^a   Williams, Brent ^a   Daly, Robert N ^b   Cain, Valerie A ^c   Pieniaszek, Henry J ^c   Sy, Sherwin K B ^c   Ebling, William ^c   Simonson, Kristen ^a   Wilcox, Racehl A ^a   Kopecky, Stephen L ^a  

^a MAYO CLINIC   (United States)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [[[3 [4 (AMINOIMINOMETHYL)PHENYL] 4,5 DIHYDRO 5 ISOXAZOLYL]ACETYL]AMINO] N (BUTOXYCARBONYL)ALANINE; ADENOSINE DIPHOSPHATE; ANTIANGINA PECTORIS AGENT; ANTICOAGULANT AGENT; CYCLO(DEXTRO 2 AMINOBUTYRYL 2 N METHYLARGINYLGLYCYLASPARTYL 3 AMINOMETHYLBENZOIC ACID) METHANESULFONATE; FIBRINOGEN RECEPTOR ANTAGONIST; PLACEBO; ROXIFIBAN;

ADULT; ANAMNESIS; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EPISTAXIS; FEMALE; GASTROINTESTINAL DISEASE; GINGIVA BLEEDING; HEART MUSCLE ISCHEMIA; HEART PALPITATION; HEMATURIA; HUMAN; INCIDENCE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MELENA; MULTIPLE DRUG DOSE; POPULATION RESEARCH; PRIORITY JOURNAL; PURPURA; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; STABLE ANGINA PECTORIS; STATISTICAL SIGNIFICANCE; THORAX PAIN; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE DISORDER; THROMBOCYTOPENIA; URINARY TRACT DISEASE;

AGED; AMIDINES; ANGINA PECTORIS; BLEEDING TIME; CORONARY ARTERY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX;

EID: 0037981388     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200303020-00004     Document Type: Article

References (37)

1. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-61
2. EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689-96
3. Collaborative overview of randomised trials of antiplatelet therapy: I. Antiplatelet Trialists' Collaborationprevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106
4. Hamm CW, Heeschen C, Goldmann B, et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. N Engl J Med 1999; 340: 1623-9
5. Heeschen C, Hamm CW, Bruemmer J, et al. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina Refractory to standard treatment trial. J Am Coll Cardiol 2000; 35: 1535-42
6. Tan WA, Moliterno DJ. Aspirin, ticlopidine, and clopidogrel in acute coronary syndromes: underused treatments could save thousands of lives. Cleve Clin J Med 1999; 66: 615-8, 621-4, 627-8
7. Creager MA. Results of the CAPRIE trial: efficacy and safety of clopidogrel. Clopidogrel versus aspirin in patients at risk of ischaemic events. Vasc Med 1998; 3: 257-60
8. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39
9. Clopidogrel in Unstable Angina to Prevent Events (CURE) Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment evaluation. N Engl J Med 2001; 345 (7): 494-502
10. Kereiakes D, Kleinman S, Ferguson J, et al. Pharmacodynamic efficacy,clinical safety, and outcomes after prolonged platelet glycoprotein iib/iiia receptor blockade with oral xemlofiban. Circulation 1998; 98: 1268-78
11. O'Neill WW, Serruys P, Knudtson M, et al. , for the EXCITE Trial Investigators. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. N Engl J Med 2000; 342: 1316-24
12. Cannon CP. Learning from the recently completed oral glycoprotein IIb/IIIa receptor antagonist trials. Clin Cardiol 2000; 23 Suppl VI: VI-14-7
13. Kereiakes DJ. Oral blockade of the platelet glycoprotein IIb/IIIa receptor: fact or fancy? Am Heart J 1999; 138 (1 Pt 2): S39-46
14. Mousa SA, Bozarth JM, Forsythe MS. Comparative in vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet-mediated clot strength induced by tissue factor with use of thromboelastography: differentiation among glycoprotein IIb/IIIa antagonists. Arterioscler Thromb Vasc Biol 2000; 20: 1162-7
15. Mousa SA, Bozarth JM, Naik UP, et al. Platelet GPIIb/IIIa binding characteristics of small molecule RGD mimetic: distinct binding profile for Roxifiban. Br J Pharmacol 2001; 133: 331-6
16. Pieniaszek Jr HJ, Sy SK, Ebling W, et al. Safety, tolerability, pharmacokinetics, and time course of pharmacologic response of the active metabolite of roxifiban, XV459, a glycoprotein IIb/IIIa antagonist, following oral administration in healthy volunteers. J Clin Pharmacol 2002; 42: 738-53
17. Kleiman NS. Pharmacokinetics and pharmacodynamics of glycoprotein IIb-IIIa inhibitors. Am Heart J 1999; 138: 263-75
18. Phillips DR, Teng W, Arfsten A, et al. Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation 1997; 96: 1488-94
19. Mousa SA, Bozarth JM, Forsythe MS, et al. Differential antiplatelet efficacy for various GPIIb/IIIa antagonists: role of plasma calcium levels. Cardiovasc Res 2000; 47: 819-26
20. Bednar B, Cook JJ, Holahan MA, et al. Fibrinogen receptor antagonist-induced thrombocytopenia in chimpanzee and rhesus monkey associated with preexisting drug-dependent antibodies to platelet glycoprotein IIb/IIIa. Blood 1999; 94: 587-99
21. Billheimer JT, Dicker IB, Wynn R, et al. Evidence that thrombocytopenia observed in humans treated with orally bioavialable glycoprotein IIb/IIIA antagonists is immune mediated. Blood 2002 May 15; 99 (10): 3540-6
22. Seiffert D, Stern AM, Ebling W, Rossi RJ, Barrett YC, Wynn R, Hollis GF, He B, Kieras CJ, Pedicord DL, Cromley DA, Hua TA, Stein RB, Daly RN, Sferruza A, Pieniaszek HJ, Billheimer JT. Prospective testing for drug-dependent antibodies reduces the incidence of thrombocytopenia observed with the small molecule glycoprotein IIb/IIIa antagonist Roxifiban: implications for the etiology of thrombocytopenia. Blood 2003 Jan; 101 (1): 58-63
23. Topol EJ, Plow EF. Clinical trials of platelet receptor inhibitors. Thromb Haemost 1993; 70: 94-8
24. Mousa SA, Forsythe M, Lorelli W, et al. Novel nonpeptide antiplatelet glycoprotein IIb/IIIa receptor antagonist, DMP754: receptor binding affinity and specificity. Coron Artery Dis 1996; 7: 767-74
25. Mousa SA, Kapil R, Mu DX. Intravenous and oral antithrombotic efficacy of the novel platelet GPIIb/IIIa antagonist roxifiban (DMP754) and its free acid form, XV459. Arterioscler Thromb Vasc Biol 1999; 19: 2535-41
26. Mousa S, Reilly TM. Antiplatelet effects of direct thrombi inhibitors versus GPIIb/IIIa receptor antagonists: comparative analysis. In: Gallo LL, editor. Cardiovascular disease: cellular and molecular mechanisms, prevention, treatment. New York (NY): Plenum Press, 1995: 255-267
27. Cannon CP, Mitchell J, McCahan J, et al. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial: thrombolysis in myocardial infarction. J Am Coll Cardiol 1999; 33: 634-9
28. Mousa SA, Abulencia JP, McCarty OJ, et al. Comparative efficacy between the glycoprotein IIb/IIIa antagonists roxifiban and orbofiban in inhibiting platelet responses in flow models of thrombosis. J Cardiovasc Pharmacol 2002 Apr; 39 (4): 552-60
29. Peter K, Schwarz M, Ylanne J, et al. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (IIbbeta3) inhibitors. Blood 1998; 92: 3240-9
30. Frelinger III AL, Furman MI, Krueger LA, et al. Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation. Circulation 2001 Sep 18; 104 (12): 1374-9
31. O'Neill WW, Serruys P, Knudtson M, et al. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators: Evaluation of oral xemilofiban in controlling thrombotic events. N Engl J Med 2000; 342: 1316-24
32. Cannon CP, McCabe CH, Wilcox RG, et al. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation 2000; 102: 149-56
33. SYMPHONY Investigators . Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. Lancet 2000; 355 (9201): 337-45
34. Hughes S. BRAVO trial stopped: lotrafiban increases mortality. Available from URL: http://www.theheart.org/index.cfm
35. Quinn MJ, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword? Circulation 2002 Jul 16; 106 (3): 379-85
36. Theroux P. Oral inhibitors of platelet membrane receptor glycoprotein IIB/IIIa in clinical cardiology: issues and opportunities. Am Heart J 1998 May; 135 (5 Pt 2 Su): S107-12
37. Vorchheimer DA, Fuster V. Oral platelet glycoprotein IIb/IIIa receptor antagonists: the present challenge is safety. Circulation 1998; 97: 312-4